Gilead Sciences' shares surged 7% after the company announced its experimental twice-yearly HIV prevention medicinedemonstrated 100% effectivenessin a late-stage trial. None of the nearly 2,000 women who got the lenacapavir shot in the trial had contracted HIV, an interim analysis showed. The in...